Molecular Variants of Soluble Guanylyl Cyclase Affecting Cardiovascular Risk

DOI Web Site Web Site PubMed 66 References
  • Wobst Jana
    Department of Cardiovascular Diseases, German Heart Center Munich, Technical University Munich
  • Rumpf Philipp Moritz
    Department of Cardiovascular Diseases, German Heart Center Munich, Technical University Munich
  • Dang Tan An
    Department of Cardiovascular Diseases, German Heart Center Munich, Technical University Munich
  • Segura-Puimedon Maria
    Institute for Integrative and Experimental Genomics, University of Lübeck
  • Erdmann Jeanette
    Institute for Integrative and Experimental Genomics, University of Lübeck German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck
  • Schunkert Heribert
    Department of Cardiovascular Diseases, German Heart Center Munich, Technical University Munich German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance

Bibliographic Information

Other Title
  • FOCUS REVIEWS ON CARDIOVASCULAR PROTECTION : Molecular Variants of Soluble Guanylyl Cyclase Affecting Cardiovascular Risk

Search this article

Description

Soluble guanylyl cyclase (sGC) is the physiological receptor for nitric oxide (NO) and NO-releasing drugs, and is a key enzyme in several cardiovascular signaling pathways. Its activation induces the synthesis of the second messenger cGMP. cGMP regulates the activity of various downstream proteins, including cGMP-dependent protein kinase G, cGMP-dependent phosphodiesterases and cyclic nucleotide gated ion channels leading to vascular relaxation, inhibition of platelet aggregation, and modified neurotransmission. Diminished sGC function contributes to a number of disorders, including cardiovascular diseases. Knowledge of its regulation is a prerequisite for understanding the pathophysiology of deficient sGC signaling. In this review we consolidate the available information on sGC signaling, including the molecular biology and genetics of sGC transcription, translation and function, including the effect of rare variants, and present possible new targets for the development of personalized medicine in vascular diseases. (Circ J 2015; 79: 463–469)

Journal

  • Circulation Journal

    Circulation Journal 79 (3), 463-469, 2015

    The Japanese Circulation Society

References(66)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top